Motivation: Off-target activity commonly exists in RNA interference (RNAi) screens and often generates false positives. Existing analytic methods for addressing the off-target effects are demonstrably inadequate in RNAi confirmatory screens.
Results: Here, we present an analytic method assessing the collective activity of multiple short interfering RNAs (siRNAs) targeting a gene. Using this method, we can not only reduce the impact of off-target activities, but also evaluate the specific effect of an siRNA, thus providing information about potential off-target effects. Using in-house RNAi screens, we demonstrate that our method obtains more reasonable and sensible results than current methods such as the redundant siRNA activity (RSA) method, the RNAi gene enrichment ranking (RIGER) method, the frequency approach and the t-test.
Contact: xiaohua_zhang@merck.com
Supplementary Information: Supplementary data are available at Bioinformatics online.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202303 | PMC |
| http://dx.doi.org/10.1093/bioinformatics/btr474 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integrins are a large family of heterodimeric receptors important for cell adhesion and signaling. Integrin α5β1, also known as the fibronectin receptor, is a key mediator of angiogenesis and its dysregulation is associated with tumor proliferation, progression, and metastasis. Despite numerous efforts, α5β1-targeting therapeutics have been unsuccessful in large part due to efficacy and off-target effects.
View Article and Find Full Text PDFBispecific antibodies and CLEM: an analytical approach to advanced cell imaging for therapeutic strategies.
Appl Microsc
January 2025
Kangwon Center for Systems Imaging, Kangwondaehak-gil, Chuncheon-si, Gangwon-do, 24341, Republic of Korea.
The development of bispecific antibodies (BsAbs) represents a significant advancement in therapeutic antibody design, enabling the simultaneous targeting of two different antigens. This dual-targeting capability enhances therapeutic efficacy, particularly in complex diseases like cancer, where tumor heterogeneity presents a significant challenge for traditional treatments. By bridging two distinct pathways, BsAbs can improve specificity and minimize off-target effects, making them invaluable in therapeutic contexts.
View Article and Find Full Text PDFElucidating a Tumor-Selective Nanoparticle Delivery Mechanism at the Colorectal Lumen-Tumor Interface for Precise Local Cancer Therapy.
Small
January 2025
College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, 46241, Republic of Korea.
Although various colorectal cancer (CRC)-targeted nanoparticles have been developed to selectively deliver anticancer agents to tumor tissues, severe off-target side effects still persist due to unwanted systemic nanoparticle distribution, limiting the therapeutic outcome. Here, by elucidating a tumor-selective nanoparticle delivery mechanism occurring at the colorectal lumen-tumor interface, an alternative CRC-targeted delivery route is proposed, which enables highly tumor-selective delivery without systemic distribution, through direct drug delivery from the outside of the body (colorectal lumen) to tumors in the colorectum. Owing to the presence of accessible tumor-specific receptors such as CD44 at the colorectal lumen-tumor interface, but not at the colorectal lumen-normal tissue interface, colorectal luminal surface (CLS)-targeting ligand-functionalized nanoparticles selectively accumulate in CRC tissues without systemic distribution, resulting in successful local CRC therapy.
View Article and Find Full Text PDFPolymeric Anti-Antibiotic Microparticles to Prevent Antibiotic Resistance Evolution.
Small
January 2025
Department of Chemical Engineering, The Pennsylvania State University, University Park, PA, 16802, USA.
Vancomycin (VAN) and daptomycin (DAP) are among the last-resort antibiotics for treating multidrug-resistant Gram-positive bacterial infections. They are administered intravenously (IV); however, ≈5 - 10% of the total IV dose is released in the gastrointestinal (GI) tract via biliary excretion, driving resistance emergence in commensal Enterococcus faecium (E. faecium) populations.
View Article and Find Full Text PDFRadiotherapy toxicities: mechanisms, management, and future directions.
Lancet
January 2025
Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
For over a century, radiotherapy has revolutionised cancer treatment. Technological advancements aim to deliver high doses to tumours with increased precision while minimising off-target effects to organs at risk. Despite advancements such as image-guided, high-precision radiotherapy delivery, long-term toxic effects on healthy tissues remain a great clinical challenge.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!